Brief: Erasca Q3 Basic EPS USD -0.11
Brief: Erasca Q2 Basic EPS USD -0.29
Brief: Erasca Initiates Seacraft-2 Pivotal Phase 3 Trial Evaluating Naporafenib Plus Trametinib In Patients With Nras-Mutant Melanoma
Brief: Erasca Announces Pricing Of Underwritten Offering Of Common Stock
Brief: Erasca Says Entered Into Exclusive License Agreement With Guangzhou Joyo Pharmatech
Brief: Erasca Files Prospectus For Proposed Resale, Other Disposition By Selling Securityholders Of Up To 21.1 Mln Shares
Brief: Erasca Q1 Basic EPS USD -0.23
Brief: Erasca Q4 Basic EPS USD -0.2
Erasca rises on trial and supply collaboration with Novartis
Brief: Erasca Announces Two Clinical Trial Collaboration And Supply Agreements
Brief: Erasca Achieves Key Milestones For Naporafenib And ERAS-801 Programs And Extends Cash Runway
Brief: Erasca Q3 Basic EPS USD -0.2
Brief: Erasca Doses First Patient In Seacraft-1 Phase 1B Trial Evaluating Naporafenib Plus Trametinib In Patients With Ras Q61x Solid Tumors
Brief: Erasca Q2 Basic EPS USD -0.21
Brief: Erasca Gets FDA Orphan Drug Designation for CNS-Penetrant EGFR Inhibitor ERAS-801
Brief: Erasca Provides Update On Clinical Program For ERK Inhibitor ERAS-007
U.S. RESEARCH ROUNDUP- Kenvue, Universal Health Services, Workday
Brief: Erasca Inc Says David Chacko Has Been Promoted To Dual Position Of Chief Financial Officer And Chief Business Officer
Brief: Erasca Reports First Quarter 2023 Financial Results And Business Updates